Lutrate Depot 3.75 mg in Prostate Cancer

Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by GP Pharm. Primary endpoints: Proportion of patients achieving castration levels of plasma testosterone (<0.5 ng/mL) 4 weeks after the first administration, Proportion of patients maintaining castration levels of plasma testosterone from week 4 to study end and 2 more. Started Sep 2005; status: completed.